000178326 000__ 01547fam\a2200373\a\4500
000178326 001__ 178326
000178326 005__ 20220217103546.0
000178326 008__ 960620s1996\\\\dcu\\\\\\\\\\f000\0\eng\d
000178326 020__ $$a0160526124
000178326 035__ $$a(OCoLC)ocm34959357
000178326 035__ $$9(IS)ACX5439
000178326 035__ $$9AAU6784SI
000178326 035__ $$a178326
000178326 040__ $$aGPO$$cGPO
000178326 043__ $$an-us---
000178326 049__ $$aISUM
000178326 074__ $$a1019-A-01
000178326 074__ $$a1019-B-01 (MF)
000178326 0860_ $$aY 4.C 73/8:104-60
000178326 088__ $$aSerial no. 104-60 (United States. Congress. House. Committee on   Commerce)
000178326 1101_ $$aUnited States.$$bCongress.$$bHouse.$$bCommittee on Commerce.$$bSubcommittee on Oversight and Investigations.
000178326 24510 $$aCancer patient access to unapproved treatments :$$bhearing before  the Subcommittee on Oversight and Investigations of the Committee on Commerce,  House of Representatives, One Hundred Fourth Congress, second session, February 29, 1996.
000178326 260__ $$aWashington :$$bU.S. G.P.O. :$$bFor sale by the U.S. G.P.O., Supt. of Docs., Congressional Sales Office,$$c1996.
000178326 300__ $$aiii, 71 p. ;$$c24 cm.
000178326 500__ $$aDistributed to some depository libraries in microfiche.
000178326 500__ $$aShipping list no.: 96-0254-P.
000178326 500__ $$a"Serial no. 104-60."
000178326 650_0 $$aCancer$$xPatients$$zUnited States.
000178326 650_0 $$aCancer$$xTreatment$$zUnited States.
000178326 650_0 $$aAntineoplaston treatment$$zUnited States.
000178326 650_0 $$aTherapeutics, Experimental$$zUnited States.
000178326 650_0 $$aAntineoplastic agents$$zUnited States.
000178326 650_0 $$aClinical trials$$zUnited States.
000178326 85230 $$bdfich$$hY 4.C 73/8$$i104-60
000178326 909CO $$ooai:library.usi.edu:178326$$pGLOBAL_SET
000178326 948__ $$ac:jb
000178326 980__ $$aBIB
000178326 980__ $$aGOV RESOURCE